New drug combo for high-risk LCH in children
Part of Blood & lymphatic, Lungs & breathing clinical trials.
This trial tests a combination of targeted therapy (dabrafenib or trametinib) with chemotherapy (clofarabine) for children with Langerhans cell histiocytosis (LCH) that is high-risk, has come back, or is not responding to other treatments. The goal is to see if this combination can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Children aged 0 to 18 years old
- Diagnosed with LCH (confirmed by special tests)
- Either newly diagnosed with LCH that has spread to blood, liver, or spleen, or LCH that got worse or came back after previous treatment
- Willing to receive treatment and come for follow-up visits
- Generally well enough for chemotherapy (based on activity level scores)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called Luvometinib added to a standard chemotherapy regimen for children with Langerhans cell histiocytosis that affects multiple parts of the body. The goal is to see if the combination works better than the standard treatment alone.
This trial tests the drug luvometinib for children with a specific type of bone disease called Langerhans cell histiocytosis (LCH). It may help kids who have not been treated before and whose LCH is in certain bones, including the head, face, or spine.
This trial tests two targeted drugs (dabrafenib and trametinib) for patients whose cancer has a specific change in the BRAF gene called V600. These drugs work together to block signals that help the cancer grow. The trial is for children, teenagers, and adults with many types of cancer, except for a few common ones that already have approved treatments.
This trial tests a combination of two drugs for children and teens with Langerhans cell histiocytosis (LCH) that has not responded to standard treatments or has come back after treatment. The goal is to see if the drugs can shrink lesions and improve symptoms.
This trial tests a targeted drug called trametinib (a MEK inhibitor) for people with Langerhans cell histiocytosis (LCH) that is newly diagnosed, relapsed, or hasn't responded to other treatments. It aims to see if trametinib can better control the disease with fewer side effects.
This trial tests a study drug, FCN-159, for children with a rare blood/immune disease called Langerhans cell histiocytosis (LCH) that has not responded to standard treatment or has come back. The goal is to see if this drug can shrink the LCH lesions and help the child feel better.
Hear when a new Langerhans Cell Histiocytosis (LCH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.